Sirolimus DEB in Coronary Bifurcation Lesions

Inclusion Criteria: 1. Male or Female that ages 18-85 year old; 2. Having evidence of myocardial ischemia; 3. Voluntarily participates in this study and signs the informed consent form (ICF); 4. Sufficiently compliant with the study protocol and agreed to receive follow-up at 1 month ±7 days, 6 months ±14 days, 9 months ±30 days, 12 months ±30 days, and 24 months ±30 days, of which angiography was required at 9 months ±30 days; 5. Angiography confirmed as de novo bifurcation lesion with side-branch stenosis (diameter) ≥70%; 6. Suitable for PCI and side-branch lesions are not expected to stent implantation, and no drug-eluting balloon used for the main-branch. If a stent is implanted into the main-branch, it's usually necessary to perform a final balloon kissing on the two branches; 7. Residual stenosis of the side-branch lesion ≦50% after pre-treatment, with a TIMI flow grade 3; 8. The target vessel diameter was 2.0mm-4.0mm. Exclusion Criteria: 1. Women who is pregnant or lactating, or having a fertility plan within 1 year or are unwilling to take effective contraceptive measures; 2. Cardiogenic shock patients; 3. With hemorrhagic symptoms or active gastrointestinal ulcers, or previous stroke within 6 months, or who are expected to be unable to tolerate double-antibody therapy after interventional therapy; 4. ST-segment elevation myocardial infarction (STEMI) occurred within one week before enrollment; 5. With severe congestive heart failure or NYHA class Ⅳ heart failure; 6. With severe valvuar heart disease; 7. Heart transplant patients; 8. With renal insufficiency (creatinine \> 3.0mg/ dL or 265.2 umol /L) and/or advanced renal disease requiring dialysis; 9. With a life expectancy less than 1 year; 10. With contraindications who cannot take aspirin and/or clopidogrel and/or ticagrelor; 11. With known allergies to paclitaxel, sirolimus, contrast agents, etc.; 12. Participating in clinical trials of other drugs or devices and has not met the primary endpoint; 13. Non-target lesions cannot be processed before the target lesions or non-target lesions treatment fails; 14. Intra-stent restenosis; 15. High-risk left main disease; 16. Other patients considered by the investigator to be unsuitable for inclusion.